HURA_OUT_1 [2025-04-02 13:04:37 -0400] 3322 Bytes | 928 tokens | Cum: 928 tkns (11.60% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 1:04:36 PM on Wed Apr 02, 2025 -0400, and I'm firing up the spotlight on TuHURA Biosciences (HURA), moving from 2.91 to 3.36. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

--- COMPANY PROFILE ---
Company: TuHURA Biosciences (HURA)
IPO: 2024-10-18 (5 Months Ago)
Market Cap: $123,155,882
Shares Outstanding: 42,290,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Here's the first list of news for TuHURA Biosciences:

C1 - Apr-01-25 08:00AM - TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
C2 - Mar-11-25 08:05AM - TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors
C3 - Mar-10-25 09:00AM - TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference
C4 - Feb-19-25 09:00AM - TuHURA Biosciences, Inc. Participates in the Virtual Investor 'Top 5 for '25' On-Demand Conference
C5 - Dec-12-24 08:45AM - TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
C6 - Nov-25-24 08:35AM - TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update
C7 - Oct-23-24 08:30AM - TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
C8 - Oct-22-24 09:00AM - TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor 'New to the Street' Event

Prior AI Reports for HURA:
1. 2025-03-19 – Score: 40 – Target: 4.0000 – Highs: 3.8500 / 4.0000 / 3.97
tuhura-biosciences-potential-amidst-financial-challenges

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on TuHURA Biosciences (HURA)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

HURA_OUT_3 [2025-04-02 13:04:45 -0400] 1100 Bytes | 323 tokens | Cum: 1253 tkns (15.66% of 8k)
==========================================================================

Showing C1 (chunk 1 of 16): C1:
**TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update**
Date: Apr-01-25 08:00AM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/tuhura-biosciences-inc-reports-financial-results-for-fiscal-year-2024-and-provides-corporate-update-302416402.html

Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda®(pembrolizumab) in 1stline therapy for advanced Merkel cell carcinoma (MCC)planning to initiate enrollment in Q2 2025

MCC Phase 3 trial to be conducted under Special Protocol Assessment (SPA)Agreement with FDA

Acquisition of Kineta's Phase 2 ready, VISTA inhibiting antibody targeted forcompletion in Q2 2025

Expanded discovery team for first-in-class immune modulating Antibody Drug orPeptide Conjugate Program

TAMPA, Fla.,April 1, 2025/PRNewswire/ --TuHURA Biosciences, Inc.(NASDAQ:HURA) ("TuHURA"

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

HURA_OUT_5 [2025-04-02 13:04:46 -0400] 1007 Bytes | 302 tokens | Cum: 1722 tkns (21.52% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T12:52:08Z - TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Updat...
A2 - 2025-04-01T12:00:00Z - TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Updat...
A3 - 2025-03-28T06:44:59Z - TuHURA Biosciences (NASDAQ:HURA) Stock Price Up 1.7% - Still a Buy?...
A4 - 2025-03-19T17:06:06Z - 12 Health Care Stocks Moving In Wednesday's Intraday Session - Biodexa Pharmaceuticals (NASDAQ:BDRX)...
A5 - 2025-03-18T17:05:47Z - 12 Health Care Stocks Moving In Tuesday's Intraday Session - Gyre Therapeutics (NASDAQ:GYRE), Avenue...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

HURA_OUT_7 [2025-04-02 13:04:53 -0400] 1100 Bytes | 313 tokens | Cum: 2037 tkns (25.46% of 8k)
==========================================================================

Showing A1 (chunk 1 of 16): A1:
**TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update By Investing.com**Date: 2025-04-01Source: {'uri': 'investing.com', 'dataType': 'news', 'title': 'Investing.com'}URL: https://www.investing.com/news/press-releases/tuhura-biosciences-inc-reports-financial-results-for-fiscal-year-2024-and-provides-corporate-update-93CH-3960328Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda ®

(pembrolizumab) in 1 line therapy for advanced Merkel cell carcinoma (MCC)

planning to initiate enrollment in Q2 2025

MCC Phase 3 trial to be conducted under Special Protocol Assessment (SPA)

Agreement with FDA

Acquisition of Kineta's Phase 2 ready, VISTA inhibiting antibody targeted for

completion in Q2 2025

Expanded discovery team for first-in-class immune modulating Antibody Drug or

Peptide Conjugate Program

TAMPA, Fla.,

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

HURA_OUT_9 [2025-04-02 13:04:57 -0400] 650 Bytes | 209 tokens | Cum: 2393 tkns (29.91% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-12-19T15:30:00Z - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders
B2 - 2024-12-14T16:10:00Z - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ML, PDCO, HURA, KANT on Behalf of Shareholders
B3 - 2024-12-12T22:19:00Z - SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kineta, Inc. - KANT

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

HURA_OUT_11 [2025-04-02 13:05:00 -0400] 763 Bytes | 228 tokens | Cum: 2623 tkns (32.79% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/24/12/n42594438/shareholder-investigation-halper-sadeh-llc-investigates-shyf-ml-hura-kant-on-behalf-of-shareholderHalper Sadeh LLC is investigating potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to the proposed sales and mergers of The Shyft Group, MoneyLion Inc., TuHURA Biosciences, Inc., and Kineta, Inc.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

HURA_OUT_13 [2025-04-02 13:05:01 -0400] 1106 Bytes | 287 tokens | Cum: 2983 tkns (37.29% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-01 8-K Item2.02 Results of Oper and Fin Cond.

On April 1, 2025, TuHURA Biosciences, Inc. (the Company or TuHURA) issued a press release reporting its financial results for the year ended December 31, 2024, and providing a corporate update. A copy of the press release ...

S2 - 2025-03-31 10-K Item 7. Manage ments Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our audited CONS financial statements and related not...

S5 - 2025-03-18 8-K Item 7.01 Regulation FD Disclosure.

On March 18, 2025, representatives of TuHURA Biosciences, Inc. (the Company or TuHURA) began making presentations to investors, analysts, and others using the investor presentation attached to this Curr Report on Form 8-K as Exhibit 99.1 (...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

HURA_OUT_15 [2025-04-02 13:05:08 -0400] 1098 Bytes | 273 tokens | Cum: 3258 tkns (40.73% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item2.02 Results of Operations and Financial Condition.

On April 1, 2025, TuHURA Biosciences, Inc. (the Company or TuHURA) issued a press release reporting its financial results for the year ended December 31, 2024, and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein

The information contained in this Current Report, including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed filed for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.

Additional Information about the Proposed Transactions between TuHURA and Kineta, Inc. and Where to Find It

This document may be deemed to be solicita

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

HURA_OUT_17 [2025-04-02 13:05:21 -0400] 3434 Bytes | 894 tokens | Cum: 4280 tkns (53.50% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+----------------------+
| Volume: 41,453 | Perf Month: 61.35% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 231.79K | Perf Quarter: -21.41% | Short Float: 5.34% | ROE: -370.77% |
+---------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 0.33 | Index: - | Short Ratio: 5.51 | ROI: -226.27% |
+---------------------+-----------------------+------------------------+----------------------+
| RSI (14): 52.38 | Market Cap: 145.89M | Short Interest: 1.28M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+----------------------+
| ATR (14): 0.42 | Shs Outstand: 42.28M | Beta: 0.55 | EPS Surprise: - |
+---------------------+-----------------------+------------------------+----------------------+
| SMA20: 14.56% | Shs Float: 23.89M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+----------------------+
| SMA50: -3.71% | Inst Own: 5.11% | Sales past 5Y: 0.00% | Earnings: Apr 01 BMO |
+---------------------+-----------------------+------------------------+----------------------+
| SMA200: -41.03% | Insider Own: 43.50% | Employees: 11 | |
+---------------------+-----------------------+------------------------+----------------------+
| Perf Week: -6.18% | Insider Trans: 0.00% | Debt/Eq: 0.00 | |
+---------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: TuHURA Biosciences, Inc./NV (HURA) by Tendler Craig (Unknown Title) on 2025-03-10
- Options (Right to Buy): 151883 shares at $0 (D)

No transactions recorded.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 3.38
Average Volume: 261317.7
30-Day High: 4
30-Day Low: 1.88
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

HURA_OUT_19 [2025-04-02 13:05:26 -0400] 676 Bytes | 167 tokens | Cum: 4695 tkns (58.69% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

HURA_IN_21 [2025-04-02 13:05:26 -0400] 126 Bytes | 29 tokens | Cum: 4814 tkns (60.17% of 8k)
==========================================================================

====================================
[2025-04-02 13:05:26] # Analysis Completed
Elapsed Time: 50.19 seconds